| Segment Reporting [Text Block] |
Note 12. Business Segment Information
BioLargo has seven operating business segments, plus its corporate entity which is responsible for general corporate operations, including administrative functions, finance, human resources, marketing, legal, etc. The operational business segments are:
| | 1. | ONM Environmental -- which sells odor and volatile organic control products and services, located in Westminster, California; |
| | 2. | Clyra Medical Technologies (“Clyra Medical”) -- which develops and sells medical products based on our technologies, located in Tampa, Florida; |
| | 3. | BioLargo Engineering (BLEST) -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed, located in Oak Ridge, Tennessee; |
| | 4. | BioLargo Canada, Inc. (“BioLargo Canada”) – the main hub of our scientists researching and developing our technologies, operating out of the University of Alberta, Edmonton, Canada; |
| | 5. | BioLargo Energy Technologies, Inc. (“BETI”) – which is developing our proprietary battery technology; |
| | 6. | BioLargo Equipment Solutions & Technologies, Inc. (“BEST”) – which manages the sales and distribution of our water treatment products and related services; and |
| | 7. | BioLargo CPG LLC ("BCPG") - founded in 2026 to commercialize household consumer products based on our technologies. |
Other than ONM Environmental, none of our operating business units have operated at a profit, and therefore have required additional cash to meet its monthly expenses, funded through sales of debt or equity, research grants, and tax credits. BETI and Clyra Medical have also been funded by third party investors who invest directly in exchange for equity ownership in that entity.
The segment information for the three and six months ended June 30, 2026, and 2025, is as follows (in thousands):
| | | Three Months Ended June 30, | | | Six Months Ended June 30, | |
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Revenue | | | | | | | | | | | | | | | | |
| ONM Environmental | | $ | 471 | | | $ | 2,006 | | | $ | 895 | | | $ | 4,809 | |
| BioLargo corporate | | | 9 | | | | — | | | | 9 | | | | — | |
| BLEST | | | 1,090 | | | | 940 | | | | 1,888 | | | | 1,630 | |
| Clyra Medical | | | — | | | | — | | | | 154 | | | | — | |
| BioLargo Canada | | | 70 | | | | — | | | | 126 | | | | 8 | |
| Intersegment revenue | | | (392 | ) | | | (169 | ) | | | (709 | ) | | | (401 | ) |
| Total | | $ | 1,248 | | | $ | 2,777 | | | $ | 2,363 | | | $ | 6,046 | |
| | | | | | | | | | | | | | | | | |
| Stock option expense | | | | | | | | | | | | | | | | |
| BioLargo corporate | | $ | 472 | | | $ | 292 | | | $ | 758 | | | $ | 701 | |
| Clyra Medical | | | 250 | | | | 200 | | | | 663 | | | | 406 | |
| Total | | $ | 722 | | | $ | 492 | | | $ | 1,421 | | | $ | 1,107 | |
| | | | | | | | | | | | | | | | | |
| Depreciation expense | | | | | | | | | | | | | | | | |
| BioLargo corporate | | $ | (10 | ) | | $ | (10 | ) | | $ | (19 | ) | | $ | (19 | ) |
| ONM Environmental | | | (9 | ) | | | (10 | ) | | | (23 | ) | | | (23 | ) |
| BLEST | | | (8 | ) | | | (11 | ) | | | (17 | ) | | | (28 | ) |
| Clyra Medical | | | (2 | ) | | | (3 | ) | | | (4 | ) | | | (4 | ) |
| BETI | | | (2 | ) | | | (2 | ) | | | (4 | ) | | | (4 | ) |
| Total | | $ | (31 | ) | | $ | (36 | ) | | $ | (67 | ) | | $ | (78 | ) |
| | | | | | | | | | | | | | | | | |
| Research and development expense | | | | | | | | | | | | | | | | |
| BioLargo corporate | | $ | (323 | ) | | $ | (219 | ) | | $ | (584 | ) | | $ | (466 | ) |
| BLEST | | | (255 | ) | | | (82 | ) | | | (463 | ) | | | (326 | ) |
| BETI | | | (156 | ) | | | (54 | ) | | | (298 | ) | | | (113 | ) |
| BioLargo Canada | | | (87 | ) | | | (120 | ) | | | (179 | ) | | | (256 | ) |
| Clyra Medical | | | (610 | ) | | | (229 | ) | | | (1,131 | ) | | | (564 | ) |
| BCPG | | | (40 | ) | | | — | | | | (40 | ) | | | — | |
| Intersegment R&D | | | 383 | | | | 169 | | | | 700 | | | | 401 | |
| Total | | $ | (1,088 | ) | | $ | (535 | ) | | $ | (1,995 | ) | | $ | (1,324 | ) |
| | | | | | | | | | | | | | | | | |
| Operating income (loss) | | | | | | | | | | | | | | | | |
| BioLargo corporate | | $ | (889 | ) | | $ | (1,045 | ) | | $ | (1,338 | ) | | $ | (1,858 | ) |
| ONM Environmental | | | (110 | ) | | | 823 | | | | (204 | ) | | | 1,780 | |
| BLEST | | | (45 | ) | | | 16 | | | | (426 | ) | | | (364 | ) |
| BETI | | | (339 | ) | | | (122 | ) | | | (694 | ) | | | (217 | ) |
| BEST | | | (75 | ) | | | (67 | ) | | | (165 | ) | | | (125 | ) |
| BioLargo Canada | | | (105 | ) | | | (144 | ) | | | (218 | ) | | | (300 | ) |
| BCPG | | | (60 | ) | | | — | | | | (60 | ) | | | — | |
| Clyra Medical | | | (2,105 | ) | | | (1,263 | ) | | | (3,826 | ) | | | (2,580 | ) |
| Total | | $ | (3,728 | ) | | | (1,802 | ) | | $ | (6,931 | ) | | $ | (3,664 | ) |
| | | | | | | | | | | | | | | | | |
| Interest income (expense) | | | | | | | | | | | | | | | | |
| BioLargo corporate | | $ | 1 | | | $ | 3 | | | $ | 64 | | | $ | 6 | |
| ONM Environmental | | | (3 | ) | | | 33 | | | | (3 | ) | | | 47 | |
| Clyra Medical | | | (270 | ) | | | (116 | ) | | | (450 | ) | | | (198 | ) |
| Total | | $ | (272 | ) | | $ | (80 | ) | | $ | (389 | ) | | $ | (145 | ) |
| | | | | | | | | | | | | | | | | |
| Net income (loss) | | | | | | | | | | | | | | | | |
| BioLargo corporate | | $ | (888 | ) | | $ | (1,042 | ) | | $ | (1,359 | ) | | $ | (1,853 | ) |
| ONM Environmental | | | (113 | ) | | | 856 | | | | (207 | ) | | | 1,827 | |
| BLEST | | | (45 | ) | | | 16 | | | | (426 | ) | | | (363 | ) |
| BETI | | | (339 | ) | | | (122 | ) | | | (694 | ) | | | (217 | ) |
| BEST | | | (75 | ) | | | (67 | ) | | | (165 | ) | | | (125 | ) |
| BioLargo Canada | | | (105 | ) | | | (144 | ) | | | (219 | ) | | | (294 | ) |
| BCPG | | | (60 | ) | | | — | | | | (60 | ) | | | — | |
| Clyra Medical | | | (2,375 | ) | | | (1,379 | ) | | | (4,275 | ) | | | (2,778 | ) |
| Total | | $ | (4,000 | ) | | $ | (1,882 | ) | | $ | (7,405 | ) | | $ | (3,803 | ) |
| As of June 30, 2026 | | BioLargo | | | ONM | | | CLYRA | | | BLEST | | | BETI | | | BioLargo Canada | | | Elimination | | | Total | |
| Tangible assets | | $ | 515 | | | $ | 1,629 | | | $ | 2,113 | | | $ | 1,248 | | | $ | 46 | | | $ | 112 | | | $ | (203 | ) | | $ | 5,460 | |
| Operating lease right-of use | | | 173 | | | | — | | | | 162 | | | | 592 | | | | — | | | | — | | | | — | | | | 927 | |
| Finance lease right-of-use | | | — | | | | — | | | | 282 | | | | — | | | | — | | | | — | | | | — | | | | 282 | |
| Total | | $ | 688 | | | $ | 1,629 | | | $ | 2,557 | | | $ | 1,840 | | | $ | 46 | | | $ | 112 | | | $ | (203 | ) | | $ | 6,669 | |
| As of December 31, 2025 | | BioLargo | | | ONM | | | CLYRA | | | BLEST | | | BETI | | | BioLargo Canada | | | Elimination | | | Total | |
| Tangible assets | | $ | 694 | | | $ | 2,331 | | | $ | 2,650 | | | $ | 1,169 | | | $ | 4 | | | $ | 321 | | | $ | (224 | ) | | $ | 6,945 | |
| Operating lease right-of use | | | 238 | | | | — | | | | 175 | | | | 615 | | | | — | | | | — | | | | — | | | | 1,028 | |
| Finance lease right-of-use | | | — | | | | — | | | | 338 | | | | — | | | | — | | | | — | | | | — | | | | 338 | |
| Total | | $ | 932 | | | $ | 2,331 | | | $ | 3,163 | | | $ | 1,784 | | | $ | 4 | | | $ | 321 | | | $ | (224 | ) | | $ | 8,311 | |
|